Nicotine Conjugate Vaccine as a Novel Approach to Smoking Cessation

Anne R. Ottney, Pharm.D


Pharmacotherapy. 2011;31(7):703-713. 

In This Article


The 3′-AmNic-rEPA vaccine represents a novel approach to smoking cessation through production of nicotine-specific antibodies that bind nicotine in the periphery, limiting distribution of nicotine to the brain and ultimately decreasing the reinforcing properties of cigarette smoking. Phase II clinical trials have demonstrated efficacy of the 3′-AmNic-rEPA vaccine in achieving smoking cessation, with higher vaccine doses showing greater efficacy. Awaiting results of phase III trials, the true clinical utility of the vaccine is yet to be realized, although the vaccine represents a distinctive administration model that may improve patient adherence and increase the ability to achieve abstinence from cigarette smoking.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.